Corporate report

Evaluating BBSRC investments in antimicrobial resistance research

This report summarises the conclusions of an expert review panel that was established to conduct an evaluation of BBSRC’s investments in AMR research.

From:
BBSRC
Published:

Documents

Evaluation of the effectiveness and impact of BBSRC’s investments in antimicrobial resistance research (PDF)

, 4 MB

If you cannot open or read this document, you can ask for a different format.

Request a different format

Email web@ukri.org, telling us:

  • the name of the document
  • what format you need
  • any assistive technology you use (such as type of screen reader).

Find out about our approach to the accessibility of our website.

Details

Bioscience research has the potential to make a critical contribution to addressing antimicrobial resistance (AMR). The Biotechnology and Biological Sciences Research Council (BBSRC) currently invests approximately £30 million each year across a variety of investment mechanisms.

This document summarises the views and 5 key conclusions of a specialist evaluation panel, who conducted an independent evaluation of the effectiveness and impact of BBSRC’s investments in AMR research.

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services.